Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Protara Therapeutics, Inc. TARA NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$12.00
+133.9%

Protara Therapeutics, Inc. (TARA) is a Biotechnology company in the Healthcare sector, currently trading at $5.13. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is TARA = $12 (+133.9% upside).

Valuation: TARA trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25).

Net income is $57M (loss), growing at -0.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $3M against $196M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 14.58 (strong liquidity). Debt-to-assets is 1.6%. Total assets: $209M.

Analyst outlook: 5 / 5 analysts rate TARA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$12.00
▲ 133.92% Upside
Average Price Target
The 12-month price target for Protara Therapeutics, Inc. is $12.00.

TARA SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TARA

✓
VALUE Pass
100/100
TARA trades at a trailing Price-to-Earnings (P/E) of -4.1 (S&P 500 average ~25). Forward PEG -1.39 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $12, implying +133.9% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
TARA: +0%/yr revenue is, -0.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet TARA: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 14.58 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
TARA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 5 / 5 analysts rate TARA as buy (100%). Analyst consensus target is $12 (+133.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.77-7.82
Volume656.91K
Avg Volume (30D)1.03M
Market Cap$197.96M
Beta (1Y)1.50
Share Statistics
EPS (TTM)-1.34
Shares Outstanding$42.84M
IPO Date2014-10-22
Employees28
CEOJesse Shefferman
Financial Highlights & Ratios
Gross Profit$-362K
EBITDA$-64.19M
Net Income$-57.44M
Operating Income$-64.55M
Total Cash$155.55M
Total Debt$3.36M
Net Debt$-46.3M
Total Assets$209.47M
Price / Earnings (P/E)-3.8
Analyst Forecast
1Y Price Target$12.00
Target High$12.00
Target Low$12.00
Upside+133.9%
Rating ConsensusBuy
Analysts Covering5
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS74365U1079

Price Chart

Track all markets on TradingView
TARA
Protara Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
2.77 52WK RANGE 7.82

People Also View

SRRK
SRRK
Scholar Rock Holding Corporation
$49.53
+0.02%
 TRVI
TRVI
Trevi Therapeutics, Inc.
$14.04
+5.33%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.92
+3.28%
 SRZN
SRZN
Surrozen, Inc.
$31.07
+4.05%
 VACC
VACC
Vaccitech plc
$5.00
+11.36%
 MIRO
MIRO
Miromatrix Medical Inc.
$3.39
+0.59%
 XLO
XLO
Xilio Therapeutics, Inc.
$8.59
+1.54%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message